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Complement regulation in the rat glomerulus: Crry and CD59 regulate
complement in glomerular mesangial and endothelial cells. The comple-
ment regulators, decay accelerating factor, membrane cofactor protein,
and CD59 are present in human glomeruli. CrIy is the rodent analogue to
the former two proteins. In this study, we examined complement regula-
tion in cultured rat glomerular endothelial cells (GEnC) and mesangial
cells (MES). Immunoprecipitation of 'I-labeled membrane proteins and
Western blotting studies were performed with anti-Crry and anti-CD59. In
both GEnC and MES, Criy was present as 53, 65, and 78 kD proteins. The
20 kD CD59 was apparent in GEnC. CD59 was also present in MES, but
in relatively smaller quantities. By Northern analyses, 1.8kb CD59 mRNA
was present in GEnC as well as in RNA from isolated rat glomeruli.
mRNA for Crry was present in both GEnC and MES as 2.2 kb species.
The functional significance of these proteins was evaluated next. Anti-Thy
1.1 IgG was used to activate the complement classical pathway in MES. To
inhibit the function of the complement regulators, anti-CD59 and/or
anti-Crry F(ab')2 antibodies were added with anti-Thy 1.1. Inhibition of
Criy function led to enhanced cytotoxicity, while there was no effect when
CD59 function was inhibited. The complement alternative pathway was
studied by adding complement in Mg-EGTA buffer. Inhibition of Crry led
to productive alternative pathway activation, which was accentuated by
anti-CD59 when Crry was incompletely inhibited. Alternative pathway
regulation was also evaluated in GEnC. Inhibition of CD59 function alone
had no effect in GEnC, while inhibition of Crry led to significant
cytotoxicity from alternative pathway activation. Under conditions in
which Criy was inactive, inhibition of CD59 further enhanced cytotoxicity.
Therefore, Crry is present in both GEnC and MES and restricts the
complement alternative pathway in both cell types. Crry also regulates the
classical pathway in MES. CD59 is present and functionally active in
GEnC, while it appears to have a minor role in MES.
The complement regulators, membrane cofactor protein
(MCP) [1, 2], decay accelerating factor (DAF) [3], and CD59 [4]
are present in the human glomerulus as shown by immunohisto-
logical techniques. The former two function to reduce C3/C5
convertase activity [5, 6], while CD59 inhibits the formation of the
C5b-9 membrane attack complex [7, 81. In the human glomerulus,
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CD59 is apparent in visceral glomerular epithelial cells (GEpC)
and glomerular endothelial cells (GEnC) [4, 9, 101. MCP is widely
distributed in human glomeruli, present in GEpC, mesangial cells
(MES), and GEnC [1, 2, 10]. DAF is predominantly expressed in
the juxtaglomerular apparatus under normal conditions, with
minor amounts in the glomerular capillary [3, 10]. The expression
of DAF becomes more diffuse in various glomerular disease states
[3]. Similar apparent up-regulation occurs with MCP under
pathological conditions in which complement activation occurs
[2]. We have previously shown that both DAF and CD59 are in
cultured human GEpC, and function to limit complement activa-
tion [9, 11].
Comparable to its distribution in the human glomerulus, rat
CD59 has strong expression in the glomerular capillary [12, 13]. It
has now become evident that DAF and MCP are absent in
rodents, and that the protein known as Crry serves the comple-
ment regulatory role of both proteins [14—17]. Crry is expressed in
the mouse glomerulus, most conspicuously in the mesangium [15].
In this study we examined the complement regulatory proteins,
Crry and CD59, in cultured rat MES and GEnC in vitro, and in the
rat glomerulus in vivo.
Methods
Antibodies and serum
Rabbit polyclonal anti-Crry antibodies were generated against
recombinant soluble mouse Crry [15]. Mouse monoclonal anti-rat
CD59 antibody clones 6D1 and TH9 were prepared as described
previously [18]. Clone 6D1, which inhibits the function of CD59
[18], was used in the functional studies. Rabbit anti-human CR1
antibodies were obtained from Harlan Bioproducts for Science
(Indianapolis, IN, USA). Rabbit anti-rat Thy 1.1 antibodies were
from Accurate Scientific (Westbury, NY, USA). Rabbit IgG
antibodies were isolated from whole antisera by protein G-
Sepharose affinity chromatography, while mouse IgG antibodies
were isolated from ascites by protein A-Sepharose affinity chro-
matography (Pharmacia, Piscataway, NJ, USA). To generate
F(ab')2 fragments, anti-Crry IgG was isolated by protein A affinity
chromatography and digested with pepsin (100:1, wt:wt; 37°C; 16
hr). Undigested IgG was retained on a protein A column. By
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SDS-PAGE under reducing conditions, there were no heavy
chains in anti-Crry F(ab')2. Normal rat serum (NRS) was ob-
tained from Sprague-Dawley rats and was used as the source of
complement in these studies. For some experiments, the comple-
ment in NRS was inactivated by heating to 56°C for 30 minutes.
Cell culture
Cultured rat MES were a gift from Dr. Andrey Cybuisky (Royal
Victoria Hospital, Montreal, Canada) [19]. MES were grown on a
plastic substratum in the presence of Dulbecco's modified Eagle
medium (Life Technologies, Gaithersbug, MD, USA) with 10%
fetal bovine serum (Sigma Chemical Co., St. Louis, MO, USA).
Rat GEnC were isolated, cloned by limiting dilution, and charac-
terized as described elsewhere [20]. Cells were grown on culture
dishes coated with fibronectin (Collaborative Research, Bedford,
MA, USA) in RPMI-1640 medium (Life Technologies) with 10%
fetal bovine serum and 10% Nu-Serum (Collaborative Research).
Single lines of MES and GEnC were used in these studies. MES
and GEnC were used between passages 13 to 20 and 15 to 17,
respectively. Cultured rat glomerular epithelial cells (GEpC),
used in Northern analyses, were cultured and characterized as
described previously [21].
Immunoprecipitation studies
Membrane proteins of GEnC and MES were labeled with 1251
as follows. Confluent cells in 100 mm culture dishes were washed
with phosphate buffered saline (PBS) and then incubated at room
temperature in 2 ml PBS to which 50 jig lactoperoxidase (Sigma),
0.5 mCi Na'251 (Amersham Corp., Arlington Heights, IL, USA),
and 50 jil 0.03% H202 were added. After three minutes, 25 jig
lactoperoxidase and 50 jil 0.03% H202 were added. Three more
aliquots of 50 jd 0.03% H202 were added at three minute
intervals. During the labeling procedure, dishes were intermit-
tently shaken. Three minutes following the last addition of H2O2,
the reaction was stopped by washing cells four times with PBS
containing 5 mivi K1. Cells were then incubated in PBS containing
1 mM EDTA for 20 minutes at room temperature with periodic
agitation, and cells not detached after this time were removed
from the substratum with a rubber policeman. Cells were washed
with PBS, and then solubilized for 15 minutes on ice in 1 ml PBS,
pH 7.2, containing 10 m'n EDTA, 10 mii iodoacetamide (Sigma),
5 mM diisopropylfluorophosphate (Sigma), 1% NP-40. Nuclei and
cytoplasmic debris were pelleted at 14,000 x g. An additional
5 jiM diisopropylfluorophosphate was added to the supernatant
containing solubilized radiolabeled membrane proteins. Unincor-
porated Na'25! was removed by chromatography on 5 ml columns
of Sephadex G-25 (Pharmacia). By this technique, an average of
1.6 x 106 and 4.0 x 106 cpm per culture dish were obtained from
MES and GEnC, respectively.
Labeled proteins were immunoprecipitated as detailed else-
where [22]. Briefly, after preclearing of antigens with normal
rabbit serum and protein G-Sepharose, antigens were immuno-
precipitated with 200 jig anti-Crry IgG or anti-CR1 IgG, 100 jig
anti-CD59 IgG, or 200 jig nonimmune rabbit IgG as a control,
followed by addition of 50 jil protein G-Sepharose (50% vol/vol).
After thorough washing, immunoprecipitated proteins were dis-
solved in reducing Laemmli sample buffer [23], and electropho-
resed through 4 to 15% gradient acrylarnide gels. The gels were
dried and then exposed for 25 days at —70°C to X-Omat film
(Eastman Kodak Co, Rochester, NY, USA) with intensifying
screens.
Western blotting
Western blotting of MES and GEnC proteins with anti-CD59
was accomplished by the following technique. Confluent MES and
GEnC in 100 mm culture dishes were detached and solubilized
exactly as described above for surface-labeled cells. Protein
content was determined using a bicinchoninic acid assay (Pierce
Chemical Co., Rockford, IL, USA). Solubilized MES and GEnC
proteins were dissolved in reducing sample buffer and different
concentrations were electrophoresed through a 12.5% acrylarnide
gel. Purified CD59 from rat eiythrocytes (10 ng) was included as
a positive control. Proteins were electrophoretically transferred to
a nitrocellulose membrane. The membrane was blocked in 5%
(wt/vol) non-fat milk in PBS, 0.1% Tween-20, and then incubated
overnight in a mixture of 5 jig/rn! each of 6D1 and TH9 anti-rat
CD59 in PBS/0.1% Tween-20. Following extensive washing with
PBS/0.1% Tween-20, bound mouse IgG was detected with a
1:2000 dilution of horseradish peroxidase-conjugated goat anti-
mouse IgG (Biorad Laboratories, Richmond, CA, USA) which
was developed with o-phenylenediamine (Sigma).
Northern blot analyses
Total RNA was obtained from cultured MES and GEnC by a
single-step guanidiniurn isothiocyanate-phenol-chloroform ex-
traction (Tn-Reagent LS, MRC, Inc., Cincinnati, OH, USA).
Three ml of Tn-Reagent LS was added directly to each 100 mm
culture dish containing confluent cells. After five minutes, the
denatured cell components were pooled and chloroform was
added (0.8 ml per culture dish). RNA in the aqueous phase was
precipitated with isopropanol and washed with ethanol. Glorner-
ular and cultured rat GEpC RNA were isolated as described
previously, except that Tn-Reagent (MRC) was used as the
source of guanidinium isothiocyanate-phenol [24]. Poly(A)
RNA was purified by affinity chromatography on oligo-dT cellu-
lose columns (MRC).
One microgram of poly(A) RNA from cultured glomerular
cells or 3.5 jig of poly(A) RNA from rat glomeruli were
electrophoresed through 1.0% agarose gels containing 2.2 M
formaldehyde. A lane containing RNA standards (Life Technol-
ogies) was run in parallel. RNA was transferred by capillary action
to a nylon membrane and cross linked to the membrane by
ultraviolet irradiation.
The full-length cDNA for rat CD59, rCD59.1 [25], was used to
probe for CD59 mRNA. The pBluescript SK phagemid was
digested with RpnI and BamHI, and the 1.5 kb rCD59.1 cDNA
insert was isolated by preparative agarose gel electrophoresis.
Liver 10 cDNA, which is a full-length nucleotide probe for mouse
Crry [26], was isolated as described elsewhere [24]. cDNA probes
were random primer labeled with [a-32P]dCTP to activities of 0.8
to 1.5 x io cpm/jig. Hybridization, washing, and stripping of
membranes were performed as described previously [24]. High
and low stringency conditions were used for hybridizations with
rCD59.1 cDNA and liver 10 cDNA, respectively [24]. To control
for the amounts of RNA loaded, hybridization with a cDNA
probe for 13-actin mRNA (a gift of Dr. Anton Schoolwerth,
Medical College of Virginia, Richmond, VA, USA) was also
performed as detailed elsewhere [24].
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Functional studies with cultured cells
Complement-mediated cytotoxicity was determined by measur-
ing the release of cell-incorporated biscarboxyethyl carboxyfluo-
rescein (BCECF; Molecular Probes, Eugene, OR, USA) from
cells into the supernatant as previously described for studies in
GEpC [11, 21]. GEnC and MES were loaded with the membrane
permeant BCECF-acetoxymethyl ester, which was deesterified
intracellularly and largely retained by viable cells. Complement-
induced BCECF release into the supernatant was measured
spectrofluorimetrically (Perkin-Elmer Co., Norwalk, CT, USA)
using excitation and emission wavelengths of 506 and 530 nm,
respectively. Specific BCECF release is expressed as a percentage
of the maximum amount of BCECF released from the same cells
lysed with melittin (0.1 j.Lg/ml, Sigma) by the equation [E — (M X
C)]I[M — (M X C)1, where E is experimental release, C is release
by control cells (expressed as a percentage of maximum releasable
BCECF from these control cells), and M is maximum release (E
plus melittin-induced release) [111.
Regulation of the alternative and classical pathways of comple-
ment was studied in MES by using inhibitory antibodies towards
Crry and CD59. Cells were studied once they were near conflu-
ence in 24-well culture dishes. Pilot studies showed that MES
viability and adherence to the substrata were optimized by using
veronal buffered saline (VBS; 145 mM NaC1, 5 mM Na barbital, pH
7.4) containing 1% bovine serum albumin (wt/vol), 1 miii CaC12,
and 0.15 mrvi MgC12 to wash cells, and by loading with BCECF and
sensitizing with antibodies in a single step in this buffer. To
evaluate alternative pathway regulation in MES, cells were sensi-
tized with various concentrations of anti-Crry IgG or anti-CD59
IgG. In another group of experiments, MES were sensitized with
0.5 mg/mI anti-Crry IgG with or without varying doses of anti-
CD59 IgU. To exclude non-specific effects of cell-bound rabbit
IgG antibody, control cells were exposed to anti-Thy 1.1 IgG.
Antibody-sensitized MES were then exposed to 40% NRS in VBS
containing 10 mM EGTA, 4 mt MgC12, and 0.1% gelatin (Mg-
EGTA-GVB) for 40 minutes at 37°C, and BCECF released into
the supernatant was measured. Complement activation in Mg-
EGTA-GVB can only occur through the alternative pathway, as
the Ca k-dependent classical pathway cannot be activated in this
buffer. To determine the complement dependence of the observed
effect, antibody-sensitized cells were also exposed to heat-inacti-
vated NRS. To assess classical pathway regulation, MES were
incubated with 0.035 mg/mI anti-Thy 1.1 IgG either alone or
together with 0.3 mg/mI anti-Crry F(ab')2 and/or 0.1 mg/mI
anti-CDS9 IgG. Neither anti-Crry F(ab')2, nor anti-CD59 IgG
[27] independently activate the classical pathway of complement.
Cells were exposed to anti-Crry and/or anti-CD59 without anti-
Thy 1.1 as controls. Antibody-sensitized cells were then incubated
in 25% NRS in GVB (VBS containing 0.15 m'vi CaC12, 0.5 mM
MgC12, and 0.1% gelatin) for 40 minutes at 37°C, and BCECF
released into the supernatant was measured. A control group that
was not antibody-sensitized but exposed to NRS was included in
each experiment evaluating alternative and classical pathway
regulation. BCECF release in these control cells exposed to NRS
was 21.2 5.0% of maximum releasable marker (mean SD of 10
separate experiments, each performed in duplicate or triplicate),
and the values from the individual experiments were used to
calculate specific BCECF release (C in the equation described
above). To determine the complement resistance of MES,
BCECF release from cells that were exposed to NRS was com-
pared to BCECF released from MES that were exposed to
heat-inactivated NRS.
To study alternative pathway regulation in GEnC, an identical
protocol to that used for MES was employed, except that 80%
NRS in Mg-EGTA-GVB was used as the complement source
(discussed below). As with MES, a control group that was not
antibody-sensitized, but exposed to NRS, was used to calculate
specific BCECF release. In experiments with GEnC, BCECF
release in these control cells exposed to NRS was 18.4 2.0% of
maximum releasable marker (mean SD of 5 separate experi-
ments, each performed in duplicate or triplicate), and the values
from individual experiments were used to calculate specific
BCECF release. Like the experiments with MES, the resistance to
complement activation was determined by comparing BCECF
released from cells exposed to NRS with that from cells exposed
to heat-inactivated NRS.
Animal experiments
Four 250 g male Sprague-Dawley rats were injected i.v. with 5
to 20 mg anti-Crry IgG. Urinary protein was measured at days 0
to 1, 1 to 2, and 4 to 5 as previously described [22]. Renal tissue
was obtained in two animals on day 1 and two animals on day 2 by
wedge biopsy of kidneys while under methoxyflurane anesthesia.
Animals were sacrificed on day 5, and renal tissue was also
obtained then. Direct immunofluorescence for rabbit IgG and rat
C3 was performed on 4 j.m cryostat sections of tissue snap-frozen
in isopentane as described elsewhere [22]. Tissue for light micros-
copy was fixed in buffered formalin, dehydrated in graded eth-
anols, cleared in xylene, and paraffin-embedded. Four micrometer
sections were stained with hematoxylin and eosin.
Statistics
All data are expressed as mean 5EM. Statistical analysis was
performed with Minitab software (State College, PA, USA).
When two groups were compared, an unpaired t-test was utilized.
When multiple groups were compared, one-way analysis of vari-
ance followed by Tukey's method of multiple comparisons was
employed. In dose-response experiments, linear, polynomial, and
logarithmic models were fit to determine if BCECF release was
significantly correlated with antibody dose.
Results
Immunoprecipitation and Western blotting experiments
1251-labeled GEnC and MES membrane proteins were immu-
noprecipitated with anti-Crry and anti-CD59. Immunoprecipita-
tions were also performed with anti-human CR1, which identifies
rat CR1 in GEpC [28]. As shown in Figure 1 (GEnC) and Figure
2 (MES), Crry was present in both cell types as identically sized
proteins of 53, 65, and 78 kD (Lane 4, arrows). Anti-human CR1
appeared to have some reactivity with Crry (Lane 3). The
presence of different sizes of Crry and cross-reactivity of anti-
human CR1 with Crry were similar to what has been observed in
the mouse [15, 29]. A faint band (not well reproduced in Fig. 1,
Lane 1) suggested the presence of the 20 kD CD59 in GEnC,
while CD59 could not be identified by this technique in MES (Fig.
2, Lane 1). Therefore, Crry is on the cell membrane of GEnC and
MES. By the techniques used in this study, CD59 was only
apparent in GEnC, but not in MES.
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Fig. 1. Autoradiogram of membrane proteins from surface-radiolabeled
cultured GEnC after immunoprecipitation with anti-CD59 (lane 1), nonim-
mune IgG (lane 2), anti-CRI (lane 3), and anti-Cny (lane 4) and separation
by SDS-PAGE (4 to 15% gradient) under reducing conditions. The straight
arrows indicate the Criy bands (53, 65, and 78 kD). The locations of the
Mr standards are shown on the left.
Western blotting studies were also performed to confirm that
CD59 was present in GEnC, and to determine whether it could be
identified in MES. As shown in Figure 3, CD59 was clearly
identified in GEnC (Lane 3; 20 g GEnC protein loaded). CD59
was very faintly identified in MES if 10 g MES protein was
loaded (Lane 1), but if 100 j.g MES protein was loaded (Lane 2),
CD59 was apparent by this technique. In Lane 4, purified eryth-
rocyte CD59 was used as a control, and shows the typical smearing
pattern of CD59 from erythrocytes, as opposed to more discrete
bands from nucleated cells [18]. Irrelevant IgG antibody did not
stain CD59 (not shown). These data show that CD59 is present in
both GEnC and MES, and that GEnC appear to contain greater
quantities of CD59.
Northern blot analyses
Northern analyses were performed on GEpC, GEnC, and MES
poly(A) RNA. As shown in Figure 4A, CD59 mRNA was
Fig. 2. Autoradiogram of membrane proteins from surface-radiolabeled
cultured MES after immunoprecipitation with anti-CD59 (lane 1), nonim-
mune IgG (lane 2), anti-CR1 (lane 3), and anti-Cny (lane 4) and separation
by SDS-PAGE (4 to 15% gradient) under reducing conditions. The arrows
indicate the Crry bands (53, 65, and 78 kD). The locations of the Mr
standards are shown on the left.
present in GEpC (Lane 1) and GEnC (Lane 2) as 1.8 kb bands
(arrow). CD59 mRNA could not be identified in MES (Fig. 4A,
Lane 3). Comparable amounts of RNA were loaded, as shown by
hybridizations with a probe for /3-actin (Fig. 4B). CD59 mRNA
was also present in glomerular poly(A) RNA (Fig. 5, arrow).
Additional hybridizations were performed with Liver 10 cDNA
for Crry. As shown in Figure 6A, Crry mRNA was present in MES
(Lane 1), GEnC (Lane 2) and GEpC (Lane 3) as a predominant
2.2 kb species (arrow).
Functional studies in cultured cells
MES were resistant to homologous complement activation, as
there was no difference in BCECF release from MES exposed to
40% NRS compared to those exposed to heat-inactivated NRS
(BCECF release = 21.5 2.1% and 18.8 1.9% of maximum
releasable, respectively; N = 4 each; P> 0.1). Therefore, BCECF
release from MES during incubation in NRS alone represents
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Fig. 3. Western blot analysis of MES and GEnC
proteins with anti-CD59. Ten tg (lane 1) and
100 .tg (lane 2) of MES protein, 20 g of
GEnC protein (lane 3), and 10 ng of purified
rat erythrocyte CD59 (lane 4) were loaded in
the respective lanes. M, Mr markers.
complement-independent leak and was used to calculate specific
BCECF release in the subsequent experiments. The following
studies were performed to determine whether the complement
regulators, Crry and CD59, which we identified in MES, are
responsible for this resistance to alternative pathway complement
activation. BCECF-loaded MES were exposed to varying doses of
anti-Crry and then to NRS in Mg-EGTA-GVB. As shown in
Figure 7, there was dose-dependent cytotoxicity in cells exposed to
anti-Crry (Fig. 7 demonstrates data fit to a second order polyno-
mial equation; P < 0.001). When cells sensitized with 1.0 mglml
anti-Crry were exposed to heat-inactivated NRS, specific BCECF
release was 3.3 1.2% (N = 5; P < 0.001 compared to cells
exposed to NRS; Fig. 7), illustrating the complement dependence
of anti-Crry-mediated cytotoxicity. When MES were exposed to
0.5 mg/ml anti-Thy 1.1 IgG and then to NRS, there was no
cytotoxicity (specific BCECF release = 0.3 0.3%; N 6),
showing that the effect of anti-Crry was specific, and not just a
consequence of IgG binding to the cell surface. These data
indicate that Crry is responsible for MES resistance to alternative
pathway activation.
To determine whether CD59 was functionally active in MES,
dose-response experiments were performed with anti-CD59. In-
hibition of CD59 function with anti-CD59 had no effect on MES
resistance to alternative pathway complement activation (Fig. 8; P
> 0.1). Because we showed that Crry is functionally active in
MES, it is possible that effective regulation of the more proximal
C3/C5 convertase formation by Crry prevented the formation of
C5b-9, which is where CD59 acts. We therefore evaluated the
effect of inhibiting CD59 function when Crry was also partially
inhibited. As shown in Figure 8, there was a significant dose-
response relationship between anti-CD59 dose and BCECF re-
lease when Crry was inhibited with 0.5 mg/ml anti-Crry (P <
0.005). These data indicate that when the function of Crry is
intact, CD59 contributes little to protecting MES from homolo-
gous complement. However, when Crry's capacity is impaired,
C5b-9 is generated, which can be restricted by CD59.
We next evaluated classical pathway activation in MES. Anti-
Thy 1.1 IgG was used to sensitize MES, as it is known to cause
complement-mediated MES injury in vivo [30]. Pilot experiments
showed that there was a dose-response relationship between
anti-Thy 1.1 dose and BCECF release (data not shown). Specific
BCECF release from MES sensitized with 0.25 mg/ml anti-Thy 1.1
IgG and subsequently exposed to 25% NRS was 79.1% (N = 2),
illustrating that classical pathway activation can overcome intrin-
sic cellular complement regulation. To determine whether Crry
and/or CD59 protect MES from classical pathway activation, MES
were sensitized with 0.035 mg/ml anti-Thy 1.1 IgG with or without
anti-Crry F(ab')2 and/or anti-CD59 IgG, and then exposed to
NRS. As shown in Table 1, at this dose of anti-Thy 1.1, there was
little cytotoxicity from classical pathway activation. Cell injury was
greatly increased if Crry was inhibited with anti-Crry. Inhibition of
CD59 with anti-CD59 did not enhance cytotoxicity in the presence
of anti-Thy 1.1, with or without anti-Cray. Therefore, in MES,
Cray serves to limit complement-mediated damage which occurs
via the classical pathway.
Similar experiments to those performed in MES were done in
GEnC to evaluate alternative pathway regulation. In pilot exper-
iments, we found that GEnC were more resistant to homologous
complement than MES, and therefore, the subsequent experi-
ments were performed with cells exposed to 80% NRS. Like MES,
GEnC effectively regulated alternative pathway activation, as
there was no difference in BCECF release from GEnC exposed to
80% NRS compared to those exposed to heat-inactivated MRS
(total BCECF release = 17.6 0.6% and 17.7 0.6% of
maximum releasable, respectively; N = 7 each). Inhibition of Cray
function with anti-Cray led to productive alternative pathway
activation in GEnC (Fig. 9 demonstrates data fit to a logarithmic
equation; P < 0.001). When cells sensitized with 0.5 mg/mI
anti-Cray were exposed to heat-inactivated NRS, specific BCECF
release was 1.5 1.5 (N = 4; P < 0.01 compared to cells exposed
to NRS; Fig. 9), illustrating the complement dependence of
anti-Cray-mediated cytotoxicity. The effect of anti-Cray appeared
to plateau beyond a dose of 0.5 mg/ml, and specific BCECF
release was never more than 20% in any single measurement.
These data illustrate that Cray is a functional complement regu-
lator in GEnC, but indicate that there were other factor(s)
responsible for GEnC complement resistance. We next studied
the effect of neutralizing CD59 function with anti-CD59. As
shown in Figure 10, there was no effect of anti-CD59 alone on
GEnC resistance to alternative pathway activation. However, if
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Fig. 5. Northern blot analysis of rat glomerularpoly(A) RNA with rCD59.1
cDNA probe. The arrow indicates the 1.8 kb CD59 mRNA. The locations
of the RNA standards are shown on the right.
formation of C3/C5 convertases in GEnC. When the function of
Crry is impaired, significant C5b-9 generation occurs, which is
regulated by CD59.
Animal experiments
Fig. 4. Northern blot analysis of poly(A )RNA from cultured GEpC (lane
1), GEnC (lane 2), an4 MES (lane 3) with rCD59.1 cDNA probe (A), and
a f3-actin cDNA (B). The arrow indicates the 1.8 kb mRNA for CD59,
present in GEpC and GEnC. The locations of RNA standards are shown
on the right.
the function of Crry was inhibited with 0.5 mg/ml anti-Crry, there
was a dose-response relationship between anti-CD59 dose and
cytotoxicity as measured by specific BCECF release (Fig. 10
illustrates data fit to a logarithmic equation; P < 0.001). Taken
together, these data indicate that Crry effectively prevents the
To determine whether Crry was present in vivo, and whether it
was accessible from the circulation, normal rats were injected i.v.
with 5 to 20 mg of anti-Criy IgG. This evidently led to intravas-
cular hemolysis, as shown by a strongly positive orthotoluidine
dipstick test for urinary hemoglobin, yet few erythrocytes visible in
the urinary sediment. There was no other adverse effect seen, and
all animals appeared normal upon recovery from anesthesia. One
day following injection, anti-Crry was diffusely localized in gb-
merular capillaries and the mesangial region (Fig. 11, dl). This
staining pattern persisted up to sacrifice (5 days following injec-
tion), although the mesangial staining became more prominent at
the later time points (Fig. 11, d5). In these later time points, the
more diffuse glomerular staining raised the possibility that anti-
Crry had been internalized by resident glomerular cells, but this
could not be confirmed with the resolution of immunofluores-
cence microscopy. Of interest is tubular basement membrane
localization of anti-Crry, which was seen in all animals at each
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Fig. 6. Northern blot analysis of poly(A )RNA from cultured MES (lane 1),
GEnC (lane 2), and GEpC (lane 3) with liver 10 cDNA probe for Criy (A),
and with a 13-actin cDNA (B). The arrow indicates the 2.2 kb Cny mRNA,
present in all three cell types. The locations of RNA standards are shown
on the right.
time point studied (Fig. 11, arrows). There was also trace focal
glomerular capillary staining for rat C3 (not shown). No morpho-
logical abnormalities were present by light microscopy at any time
point and at any dose of anti-Crry, nor did any animal develop
significant proteinuria (urinary protein < 10 mg124 hr). There-
fore, Crry appears to be present in MES and GEnC in vivo as well
as in vitro.
Discussion
In this study we have examined the complement regulators,
Crry and CD59, in rat glomerular cells. We have shown that Crry
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Fig. 8. Effect of neutralizing CD59 function on MES resistance to alternative
pathway activation. MES were exposed to varying concentrations of
anti-CD59 with (c') or without (U) 0.5 mg/ml anti-Criy. Cells were then
exposed to 40% NRS in Mg-EGTA-GVB and BCECF released into the
supernatant was measured as an indicator of complement-mediated
cytotoxicity. Data are pooled from five separate experiments, with at least
duplicate wells per experiment, and are expressed as mean SEM.
protein and mRNA are present in cultured GEnC and MES. Crry
is functionally active in both of these cells, limiting complement
activation through both alternative and classical pathways. From
the experiments in vivo, Crry also appears to be on both GEnC
and MES in rat glomeruli, consistent with the studies in cultured
cells. We have also shown that CD59 mRNA and functionally
active protein are present in GEnC. Smaller quantities of CD59
protein are present in MES that have a limited role to restrict
C5b-9-mediated cytotoxicity in these cells.
Mouse Criy is comprised of five short consensus repeats (SCR)
of approximately 60 amino acids each, which are homologous to
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Fig. 7. Effect of neutralizing Cny function on MES resistance to alternative
pathway complement activation. MES were exposed to varying concentra-
tions of anti-Criy and then to 40% NRS in Mg-EGTA-GVB. BCECF
released into the supernatant was measured as an indicator of comple-
ment-mediated cytotoxicity. To determine the complement dependence of
anti-Crry's effect, anti-Crry-sensitized cells were also exposed to heat-
inactivated NRS (HIS). Data are pooled from three separate experiments,
with at least duplicate wells per experiment, and are expressed as mean
SEM. Where not shown, the error bars fall within the data points. Symbols
are: (•) NRS; () HIS.
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Table 1. Classical pathway complement regulation in MES
Fig. 10. Effect of neutralizing CD59 function on GEnC resistance to
alternative pathway activation. GEnC were exposed to vatying concentra-
tions of anti-CD59 with (•) or without (U) 0.5 mg/mI anti-Crry. Cells
were then exposed to 80% NRS in Mg-EGTA-GVB and BCECF released
into the supernatant was measured as an indicator of complement-
mediated cytotoxicity. Data are pooled from three separate experiments,
with at least duplicate wells per experiment. All SEM bars fall within the
data points.
cells. While it has been suggested that the variability in the size of
mouse Crry may be due to differences in glycosylation [15], it is
now apparent that an alternative form of rat Criy exists that
contains an extra, duplicated SCR (R.J. Quigg, unpublished
observations). It is conceivable that the 78, 65, and 53 kD Crry
proteins in MES and GEnC we have shown in this study are
composed of 7, 6, and 5 SCR's, respectively.
The experiments showing the existence of Criy in both GEnC
and MES in vitro are supported by studies in vivo, illustrating that
Crty is present in GEnC and MES in rat glomeruli. While the
studies in cultured glomerular cells suggested that inhibition of
Crry function in vivo would lead to complement activation and
cellular injury, as well as the possibility of inflammatory cell
infiltration [33, 34], we could find little evidence for any of these
in rats injected with anti-Crry IgG. Similar results as ours were
found in a recent study by Nishikage et al in which monoclonal
anti-Crry antibodies were injected directly into the renal artery,
which led to no measurable effect [35]. However, inhibition of
Crry function with these antibodies exacerbated the anti-Thy 1.1
model of complement-mediated mesangial cell injury. These
results are entirely consistent with our studies on classical pathway
complement regulation in MES in vitro and illustrate a role for
Cny in the mesangium in vivo.
The composition of CD59 is conserved among species [25], as is
its function to prevent the assembly of the C5b-9 membrane
attack complex [7, 18, 36]. Furthermore, the diffuse distribution of
CD59 in the glomerular capillary is evident in humans [4, 10] and
rats [12]. Here we show that CD59 protein and mRNA are in
GEnC. Inhibition of the function of CD59 alone did not lead to
GEnC injury via alternative pathway activation, indicating that
Criy effectively regulated the more proximal C31C5 convertase
formation. Yet, when Crry's function was inhibited, there was
enhanced cytotoxicity when CD59 activity was also constrained.
This indicates that significant amounts of terminal complement
complexes are generated under conditions of Crry inactivity, but
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MES were loaded with BCECF and exposed to buffer (—anti-Thy 1.1)
or anti-Thy 1.1 (+anti-Thy 1.1) either alone or together with anti-Crry
and/or anti-CD59, followed by incubation in 25% NRS in GVB4.
BCECF released into the supernatant was then measured. Data were
pooled from five experiments, each performed in triplicate and are
expressed as mean SEM.
a This group was used to calculate specific BCECF release and will
therefore average 0.bConfidence intervals of these two groups with a family error rate of
0.001 were different from all other groups. No other statistically significant
differences were demonstrated.
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Fig. 9. Effect of neutralizing Criy function on GEnC resistance to alternative
pathway complement activation. GEnC were exposed to varying concen-
trations of anti-Crry and then to 80% NRS in Mg-EGTA-GVB. BCECF
released into the supernatant was measured as an indicator of comple-
ment-mediated cytotoxicity. To determine the complement dependence of
anti-Crry's effect, anti-Crry-sensitized cells were also exposed to heat-
inactivated NRS (HIS). Data are pooled from three separate experiments,
with duplicate wells per experiment, and are expressed as mean SEM.
Symbols are: (•) NRS; (A) HIS.
SCR's 1 to 4 and 30 of human CR1 [26]. While Crry has
evolutionary homology to human CR1, it appears that in the
mouse, Crry takes the place of the human complement regulators,
DAF and MCP [14—17]. Mouse Crry shares the activity of DAF
and MCP in that it is a decay accelerator of C31C5convertases
and a factor I cofactor for the cleavage and inactivation of C3b
and C4b [17]. Crry has a widespread distribution in the mouse,
and is strongly expressed in glomeruli [15]. We have previously
shown that cultured rat GEpC have Crry [24], illustrating that this
protein is present in the rat as well. Takizawa, Okada and Okada
have isolated a rat protein, termed 512 antigen [31], that undoubt-
edly is rat Crry based upon its nucleotide composition [32]. Rat
Crry is larger than mouse Crry because it contains an additional
SCR [32]. The size of mouse Crry is variable in any given tissue
[15], which we have also shown here for rat Crry in glomerular
420 Quigg et al: Complement regulation in the rat glomerulus
Fig. 11. Glomendi from rats one day (dl) and five days (d5) after injection of anti-Coy. Diffuse glomerular capillary staining for rabbit IgG is seen at both
time points. Mesangial staining is prominent on day 5. The arrows indicate linear deposition of anti-Crry along tubular basement membranes. (x400).
CD59 limits the ultimate formation of C5b-9. In a recent study by
Matsuo et a!, glomerular localization of anti-CD59 did not lead to
apparent GEnC injury [13], consistent with our studies in cultured
GEnC. Yet, in a model of glomerulonephritis in which comple-
ment was activated in the subendothelial space, anti-CD59 signif-
icantly increased the severity of glomerular injury, consistent with
a role for CD59 in limiting C5b-9-mediated GEnC injury [13].
With the techniques used in this study, we could identify only
small quantities of CD59 protein in cultured MES. Consistent
with these findings are that CD59 had only a minor role to limit
C5b-9-mediated MES injury. Although we cannot exclude that
our findings in MES in vitro were due to loss of CD59 expression
with culture, mesangial staining with anti-CD59 in human and rat
glomeruli is inconspicuous [4, 10, 12, 131, which is compatible with
our findings of only small amounts of CD59 protein in cultured
MES. We could not identify CD59 mRNA in these cells by
Northern analysis. Since CD59 protein was present in MES,
conceivable explanations for this are that the Northern analysis
was not sensitive enough to detect a small number of CD59
mRNA molecules, or that the CD59 proteins had already been
translated, and the mRNA was absent at the time of RNA
harvesting (that is, once cells were confluent). The exact role of
CD59 in MES in vivo requires further study.
Given that complement is key to many glomerular diseases [37,
38], the interplay between complement regulation and activation
is likely to be important. DAF, MCP, and CD59 are up-regulated
in the human glomerulus under pathological conditions in which
complement activation plays a role [2, 3, 39]. It is conceivable that
there are instances in which such up-regulation can limit or
prevent disease under conditions of glomerular immune complex
deposition and complement activation. Elucidation of the roles of
Criy and CD59 in the normal and diseased rat glomerulus may
provide clues to the role for complement regulation in the human
gi omerulus.
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